News Archives - Page 68 of 87

ThursdayNov 03, 2022 12:22 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) to Participate in 13th Craig-Hallum Alpha Select Conference

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 13th Craig-Hallum Alpha Select Conference. The event is slated to be held in New York City on Nov. 17, 2022. Cepton management will be available for group investor or one-on-one meetings throughout the conference. Interested parties should contact InvestorRelations@Cepton.com or their Craig-Hallum representative for related inquiries. To view the full press release, visit https://ibn.fm/kcm7E About Cepton Inc. Cepton is a Silicon Valley innovator of lidar-based solutions…

ThursdayNov 03, 2022 11:13 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

WednesdayNov 02, 2022 11:52 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

WednesdayNov 02, 2022 10:33 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Eliminates Some $13M in Debt

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has eliminated $13 million in company debt, resulting in a reduction of overall indebtedness from more than $30 million last year to less than $10 million currently. The company has been working to strengthen its financial balance sheet; it also recently eliminated some $13 million of company debt associated with Esousa Holdings LLC. According to the announcement, MULN believes this debt conversion will save more than $3.5 million in interest expenses. With less than $10 million left of outstanding indebtedness, Mullen is maintaining its strong financial health. “It’s been a…

TuesdayNov 01, 2022 1:35 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

TuesdayNov 01, 2022 1:23 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

TuesdayNov 01, 2022 12:57 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

MondayOct 31, 2022 10:17 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Shares Responses from Participants of Its Strikingly Different FIVE EV Crossover Tour

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is seeing an overwhelmingly positive response to its Strikingly Different FIVE EV Crossover tour. Tour participants, including potential buyers and Mullen investors, who reserve a spot on the tour are enjoying the opportunity to ride the Mullen EV Crossover and personally interact with Mullen’s updated infotainment system, which features PERSONA, Mullen’s proprietary Personal Vehicle Assistant technology. PERSONA uses the latest facial recognition technology, which enables the vehicle to provide a highly personalized experience to every driver of the Mullen FIVE. The tour kicked off in Pasadena, California, last week, and has…

FridayOct 28, 2022 12:39 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports Higher-than-Expected Preorders for Mullen FIVE Electric-SUV Crossover

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is accepting preorders for its Mullen FIVE vehicle, and the company’s Strikingly Different EV Crossover Tour has had a significant impact on those orders. The tour kicked off earlier this week, and preorders for the new SUV crossover quadrupled in the period leading up to and during the tour’s first stop in Pasadena, California. Those who attend the tour can take a test drive in the new EV, with a professional driver at the wheel; they also have an opportunity to interact with the vehicle’s innovative infotainment system and see…

ThursdayOct 27, 2022 1:22 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol ("CBD") therapy. The study is evaluating Lexaria's patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News